| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Emmaus Medical Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Gerigene Medical Corporation is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CALIBER THERAPEUTICS is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inogent is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.